Entera Bio Ltd. (NASDAQ: ENTX) presented preclinical data for two pipeline candidates, EB612 and EB618, at ENDO 2026, the annual ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE